Characterization of MRI response to treatment with interferon beta-1b: Contrast-enhancing MRI lesion frequency as a primary outcome measure

Neurology

Volumn 49, Issue 3, 1997, Pages 862-869

  Stone, Lael A ^a   Frank, J A ^b   Albert, P S ^c   Bash, C N ^b   Calabresi, P A ^d   Maloni, H ^d   McFarland, H F ^d  

^a MAYO CLINIC   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; INTERFERON BETA SERINE;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CORTICOSTEROID THERAPY; FEMALE; GENETIC HETEROGENEITY; HUMAN; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

EID: 0030773332     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.49.3.862     Document Type: Article

References (11)

1. Paty DW, Li DKB, UBC Study Group, IFNB Multiple Sclerosis Study Group. Interferon beta 1b is effective in relapsing-remitting multiple sclerosis. II: MRI analysis results of a multicenter, randomized, double-blind placebo-controlled trial. Neurology 1993;43:662-667.
2. Stone LA, Frank JA, Albert PS, et al. The effect of interferon-beta on blood brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing remitting multiple sclerosis. Ann Neurol 1995:37:611-619.
3. McFarland HF, Frank JA, Albert PS, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis patients. Ann Neurol 1992; 32:758-766.
4. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status score (EDSS). Neurology 1983;33:1444-1452.
5. Smith ME, Stone LA, Albert PS, et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopenetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol 1993;33:480-489.
6. Haskell CM Principles of cancer chemotherapy. In: Haskell CM, ed Cancer treatment. Philadelphia: WB Saunders. 1995.
7. Smith ME, Albert PS, Stone LA, Frank JA, McFarland HF. The use of MRI to evaluate individual heterogeneity in treatment response in multiple sclerosis. Neurology 1995;45(suppl 4):A435.
8. Arnason BGW, Jensen M, Lledo A, Dayal A. Interferon beta (IFNB) induction in multiple sclerosis (MS) increases interferon gamma (IFNG) secreting cells. Neurology 1995;45(suppl 4):A437.
9. Filippi M, Yousry T, Campi A, et al. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS. Neurology 1996;46: 379-384.
10. Campi A, Filippi M, Comi G, et al. Magnetisation transfer ratios of contrast-enhancing and nonenhancing lesions in multiple sclerosis. Neuroradiology 1996;38:115-119.
11. 1-weighted gradient echo sequence improves the detection of disease activity in multiple sclerosis. Ann Neurol 1996;40:901-907.